6 months versus 12 months of adjuvant trastuzumab for...

The Lancet Oncology 2013 / 07 Vol. 14; Iss. 8

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

Pivot, Xavier, Romieu, Gilles, Debled, Marc, Pierga, Jean-Yves, Kerbrat, Pierre, Bachelot, Thomas, Lortholary, Alain, Espié, Marc, Fumoleau, Pierre, Serin, Daniel, Jacquin, Jean-Philippe, Jouannaud, C
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
14
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(13)70225-0
Date:
July, 2013
File:
PDF, 358 KB
english, 2013
Conversion to is in progress
Conversion to is failed